# Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection

> **NCT00881517** · PHASE2,PHASE3 · COMPLETED · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 124 (actual)

## Conditions studied

- Cytomegalovirus Infection

## Interventions

- **DRUG:** HCMV-specific hyperimmune globulin (Cytotect®)
- **DRUG:** Isotonic solution of sodium chloride (placebo)

## Key facts

- **NCT ID:** NCT00881517
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 124 (ACTUAL)
- **Last updated:** 2011-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881517, "Efficacy Study of Human Cytomegalovirus (HCMV) Hyperimmune Globulin to Prevent Congenital HCMV Infection". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT00881517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*